SEER Inquiry System - Search

Primary Site--Skin:  Are perianal skin primaries within 5 cm of the anus coded as perianal skin (C44.5) or anus (C21.0).  See Discussion.

Histology--Vulva:  How is the histology coded for vulvar intraepithelial neoplasia III (VIN III)/Squamous cell carcinoma in situ from a pathology report of the vulva, 8070/2 for squamous cell carcinoma in situ or 8077/2 for VIN III?  The rules do not discuss this particular situation. 

Solid Tumor Rules/Multiple Primaries--Peripheral Nerves: How many primaries should be abstracted, and which M Rule applies, when a malignant peripheral nerve sheath tumor (MPNST) in the right arm (C471) is followed greater than one year later by a separate malignant peripheral nerve sheath tumor of the thoracic chest wall (C473)?  See Discussion.

Solid Tumor Rules/Multiple Primaries--Prostate:  How many primaries should be abstracted, and which M rule applies when a patient is diagnosed with intraductal carcinoma of the prostate on biopsy followed by invasive adenocarcinoma on radical prostatectomy more than 60 days later? See Discussion.

Histology--Cervix: Can human papilloma virus (HPV) or p16 testing results from a non-reportable high-grade squamous intraepithelial lesion (HSIL)/cervical intraepithelial neoplasia  (CIN 3) pathology report be used to code histology as squamous cell carcinoma (SCC), HPV-positive (8085), if subsequent excision/resection identifies invasive SCC and no further HPV or p16 testing is done on the invasive specimen? See Discussion.

SEER Manual/Reportability--Brain and CNS:  Is microadenoma reportable?  A pituitary mass seen on imaging was "consistent with Microadenoma" on 11/15/2022.  There was no histologic confirmation or treatment given.

Solid Tumor Rules/Multiple Primaries—Brain and CNS:  How many primaries are accessioned, and which M Rule applies, to a 2018 pituitary adenoma (8272/0) that was partially resected followed by a 2023 resection of residual disease proving pituitary adenoma/pituitary neuroendocrine tumor (8727/3)? See Discussion.

Solid Tumor Rules/Multiple Primaries: What M Rule of the updated Solid Tumor Rules, Other Sites, applies to a 2022 diagnosis of endometrial cancer, followed greater than one year later by a 2023 diagnosis of esophageal cancer with no interim evidence of tumor recurrence? See Discussion.

Histology--Soft Tissue:  How is histology coded for malignant neoplasm with neuroectodermal differentiation and TPR-NTRK1 gene rearrangement diagnosed on left shoulder excision? See Discussion.

First Course Treatment/Reason for No Surgery of Primary Site: How should Reason for No Surgery of Primary Site be coded for cases when surgery was planned but aborted due to extent of disease seen during planned procedure?  See Discussion.